Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Preferred Stock Liabilities (2020 - 2021)

Oncology Institute (TOI) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $230.0 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Preferred Stock Liabilities rose 13.03% year-over-year to $230.0 million, compared with a TTM value of $230.0 million through Sep 2021, up 13.03%, and an annual FY2020 reading of $230.0 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $230.0 million for Q3 2021 at Oncology Institute, up from $29.5 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $230.0 million in Q1 2020 and bottomed at $23.3 million in Q1 2021.